Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study

Rech, Tatiana Helena; Vieira, Sílvia Regina Rios; Nagel, Fabiano Marcio; Brauner, Janete Salles; Scalco, Rosana

doi:10.1186/cc5046

Cited by 69 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, detection of NSE could be useful if measured after 24-48 h of TBI [67, 68]. Other study has found that elevated levels of NSE can be detected at an earlier time, and could be used as a prognostic marker [69]. In that study, NSE levels were measured at any time between 12 and 36 h, and the authors were able to detect NSE levels as a marker of prognosis after cardiac arrest.…”

Section: Nse In Other Acute Injuries To Cnsmentioning

confidence: 96%

Neuron specific enolase: a promising therapeutic target in acute spinal cord injury

et al. 2016

View full text Add to dashboard Cite

Enolase is a multifunctional protein, which is expressed abundantly in the cytosol. Upon stimulatory signals, enolase can traffic to cell surface and contribute to different pathologies including injury, autoimmunity, infection, inflammation, and cancer. Cell-surface expression of enolase is often detected on activated monocytes/macrophages, microglia and astrocytes, promoting extracellular matrix degradation, production of pro-inflammatory cytokines/chemokines, and invasion of inflammatory cells in the sites of injury and inflammation. Inflammatory stimulation also induces translocation of enolase from the cytosolic pool to the cell surface where it can act as a plasminogen receptor and promotes extracellular matrix degradation and tissue damage. Spinal cord injury (SCI) is a devastating debilitating condition whose progressive pathological changes include complex and evolving molecular cascades, and insights into the role of enolase in multiple inflammatory events have not yet been fully elucidated. Neuronal damage following SCI could be characterized by an elevation of neuron specific enolase (NSE), which is also known to play a role in the pathogenesis of hypoxic-ischemic brain injury. Thus, NSE is now considered as a biomarker in ischemic brain damage, and it has recently been suggested to be a biomarker in traumatic brain injury (TBI), stroke and anoxic encephalopathy after cardiac arrest and acute SCI as well. This review gives an overview of current basic research and clinical studies on the role of multifunctional enolase in neurotrauma, with a special emphasis on NSE in acute SCI.

show abstract

Section: Nse In Other Acute Injuries To Cnsmentioning

confidence: 96%

Neuron specific enolase: a promising therapeutic target in acute spinal cord injury

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Comparing of the result with non infectious disease outcome, serum levels of NSE in first few days of ischemic stroke can serve as a useful marker to predict stroke severity and early functional outcome20). Study by Rech et al21) demonstrates that NSE levels measured early in the course of ischemic cerebral injury are significantly higher in patients with unfavorable outcome than in patients with favorable outcome.…”

Section: Discussionmentioning

confidence: 99%

Serum neuron specific enolase is increased in pediatric acute encephalitis syndrome

2017

View full text Add to dashboard Cite

PurposeThis study aimed to investigate whether serum neuron-specific enolase (NSE) was expressed in acute encephalitis syndrome (AES) that causes neuronal damage in children.MethodsThis prospective observational study was conducted in the pediatric neurology ward of Soetomo Hospital. Cases of AES with ages ranging from 1 month to 12 years were included. Cases that were categorized as simple and complex febrile seizures constituted the non-AES group. Blood was collected for the measurement of NSE within 24 hours of hemodynamic stabilization. The median NSE values of both groups were compared by using the Mann-Whitney U test. All statistical analyses were performed with SPSS version 12 for Windows.ResultsIn the study period, 30 patients were enrolled. Glasgow Coma Scale mostly decreased in the AES group by about 40% in the level ≤8. All patients in the AES group suffered from status epilepticus and 46.67% of them had body temperature >40℃. Most of the cases in the AES group had longer duration of stay in the hospital. The median serum NSE level in the AES group was 157.86 ng/mL, and this value was significantly higher than that of the non-AES group (10.96 ng/mL; P<0.05).ConclusionAES cases showed higher levels of serum NSE. These results indicate that serum NSE is a good indicator of neuronal brain injury.

show abstract

“…31,32 This 40–62% “noise” is likely due to intra-individual differences in CSF clearance, affected by cardiac output, 33 sleep, 34 physical activity and aging, 35–36 as well as systemic clearance and hepatic metabolism of soluble biomarkers. While this level of accuracy may be sufficient for some indications, such as providing prognostic value of recovery from CNS injury, 37 introducing 40–62% noise in pharmacodynamic outcomes in drug development or precision medicine applications may not be acceptable. At any rate, development of sensitive serum/plasma assays for CNS-specific biomarkers is welcomed, but the clinical utility of these assays needs to be evaluated against CSF assays, so that the sensitivity, specificity and correlations of these measurements to clinical outcomes are well understood.…”

Section: Biomarkersmentioning

confidence: 99%

Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping

Bielekova

Pranzatelli

2017

Seminars in Pediatric Neurology

View full text Add to dashboard Cite

Biomarkers are central to the translational medicine strategic focus, though strict criteria need to be applied to their designation and utility. They are one of the most promising areas of medical research, but the “biomarker life-cycle” must be understood to avoid false-positive and false-negative results. Molecular biomarkers will revolutionize the treatment of neurological diseases, but the rate of progress depends on a bold, visionary stance by neurologists, as well as scientists, biotech and pharmaceutical industries, funding agencies, and regulators. One important tool in studying cell-specific biomarkers is multi-parameter flow cytometry. CSF immunophenotyping, or immune phenotypic subsets, captures the biology of intrathecal inflammatory processes, and has the potential to guide personalized immunotherapeutic selection and monitor treatment efficacy. Though data exist for some disorders, they are surprising lacking in many others, identifying a serious deficit to be overcome. Flow cytometric immunophenotyping provides a valuable, available, and feasible “window” into both adoptive and innate components of neuroinflammation that is currently underutilized.

show abstract

Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study

Cited by 69 publications

References 37 publications

Neuron specific enolase: a promising therapeutic target in acute spinal cord injury

Neuron specific enolase: a promising therapeutic target in acute spinal cord injury

Serum neuron specific enolase is increased in pediatric acute encephalitis syndrome

Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping

Contact Info

Product

Resources

About